OTCQB:GBNHF - Post by User
Comment by
mjh9413on Jan 15, 2020 1:38am
332 Views
Post# 30554195
RE:SmallCapPower Article
RE:SmallCapPower ArticleJust looking at this one for first time. It is a numbers game.
Treatment costs say $220US. Most treatments are 30 in number over 6 weeks I believe.(A patient may be eligible for insured re-induction if meeting certain criteria.) Being insured or a prepaid private patient is important so receivables do not become problem.
To get to $800MM in gross revenues they would need 121,000 patients a year...that is total patients who get $220 treatment cost and 30 treatments.) Taking the Achieve purchase numbers it seems that fy2019 proforma might involve 4,600 patients.
That's one comparative look.
We can do it other way. Assume with further acquisitions and geographic spread they get 10,000 patients in a year. That's US66MM gross revs which gives 23centsCDN EBITDA/sh on 54MM shares with a 15% EBITDA margin.
That's 10,000 patients, more than twice proforma 2019 number and, of course, costs will be high in growth stage so 15% is very generous. I'll wait for next 3 qtr' numbers to see the pattern.
Any comments welcome.